Advertisement
Heart, Lung and Circulation

Does a Change in Device Design Alter Device Size Selection? A Comparison of Conventional and Occlutech Duct Occluder Designs

Published:September 08, 2022DOI:https://doi.org/10.1016/j.hlc.2022.07.007

      Aim

      The Occlutech duct occluder (ODO) with a novel design has been available for closure of patent ductus arteriosus (PDA) since 2011. Available data on initial experience with the ODO have shown that operators continue to choose device sizes based on their experience with conventional duct occluders (CDO). This study postulated that occlusion of the pulmonary arterial (PA) end of the ductus should achieve satisfactory PDA closure without additional complications. Accordingly, the size of the ODO was chosen such that the larger PA diameter in the new design exceeded the PA end of the ductus by 2–3 mm and 2–4 mm for normotensive and hypertensive ducts, respectively. It sought to examine the feasibility and safety of such an approach, and compared ODO and CDO devices with respect to device sizes deployed, to ascertain if the newer design had any advantages.

      Methods

      This prospective study enrolled 105 infants, children and a few adults with various duct morphologies and PA pressures for ductal closure using the ODO from 2018–2020. The control group consisted of 105 ducts closed with CDO. A comparison of the two groups with respect to duct diameter and implanted device sizes was performed using appropriate statistical software.

      Results

      The study found that 40% of the ducts had moderate-to-severe pulmonary hypertension. Most ducts measured between 3–4 mm in both groups. The mean weight of the subjects in both groups was 12 kg. Although there was no change in the way that duct occluders were chosen in both groups (2–3 mm over the pulmonary artery diameter), ODO could be significantly downsized in most ducts measuring between 2.5–6.4 mm in diameter (p<0.05).

      Conclusions

      This study found successful closure of relatively larger PDA in infants and children using smaller ODO compared with CDO, without embolisation or aortic narrowing. It also demonstrated that a different device size selection technique may be safely employed with the ODO.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ebeid M.R.
        • Masura J.
        • Hijazi Z.M.
        Early experience with the Amplatzer ductal occluder for closure of the persistently patent ductus arteriosus.
        J Interv Cardiol. 2001; 14: 33-36
        • Abdelbasit M.A.E.
        • Alwi M.
        • Kandavello G.
        • Che Mood M.
        • Samion H.
        • Hijazi Z.M.
        The New Occlutech PDA occluder: Initial Human experience.
        Catheter Cardiovasc Interv. 2015; 86: 94-99
        • Bilkis A.A.
        • Alwi M.
        • Hasri S.
        • Haifa A.L.
        • Kandhavello G.
        • Rehman M.A.
        • et al.
        The Amplatzer duct occluder: experience in 209 patients.
        J Am Coll Cardiol. 2001; 37: 258-261
        • Masura J.
        • Walsh K.P.
        • Thanopoulous B.
        • Chan C.
        • Bass J.
        • Goussous Y.
        • et al.
        Catheter Closure of Moderate- to Large-sized Patent Ductus Arteriosus Using the New Amplatzer Duct Occluder: Immediate and Short Term Results.
        J Am Coll Cardiol. 1998; 31: 878-882
        • Sheridan B.D.
        • Ward C.J.
        • Anderson B.W.
        • Justo R.N.
        Transcatheter closure of the patent ductus arteriosus: An intention to treat analysis.
        Heart Lung Circ. 2013; 22: 428-432
        • Krichenko A.
        • Benson L.N.
        • Burrows P.
        • Möes C.A.
        • McLaughlin P.
        • Freedom R.M.
        Angiographic classification of isolated persistently patent ductus arteriosus and implications for percutaneous catheter occlusion.
        Am J Cardiol. 1989; 63: 877-880
        • Kudumula V.
        • Taliotis D.
        • Duke C.
        The New Occlutech Duct Occluder: Immediate results, Procedural challenges, and Short term follow up.
        J Invasive Cardiol. 2015; 27
        • Boudjemline Y.
        The New Occlutech patent ductus arteriosus occluder: single centre experience.
        Arch Cardiovasc Dis. 2016; 109: 384-389
        • Bilici M.
        • Demir F.
        • Akin A.
        • Türe M.
        • Balik H.
        • Kuyumcu M.
        Transcatheter closure of patent ductus arteriosus in children with the Occlutech duct occluder.
        Pediatr Cardiol. 2017; 38: 1598-1605
        • Pepeta L.
        • Greyling A.
        • Nxele M.F.
        • Makrexeni Z.M.
        Patent ductus arteriosus closure using Occlutech duct occluder, experience in Port Elizabeth, South Africa.
        Ann Pediatr Cardiol. 2017; 10: 131-136
        • Godart F.
        • Houeijeh A.
        • Domanski O.
        • Guillaume M.P.
        • Brard M.
        • Lucron H.
        Is the new Occlutech duct occluder an appropriate device for transcatheter closure of patent ductus arteriosus?.
        Int J Cardiol. 2018; 261: 54-57
        • Sheikh A.M.
        • Shebani S.O.
        • Duke C.
        The Occlutech duct occluder: How to choose the correct device size and refine implantation technique to ensure optimal results in small and large arterial duct closure.
        Interv Cardiol. 2019; 11: 113-119